U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07333677) titled 'In Vivo CAR-T for Refractory Graves' Disease' on Dec. 20, 2025.
Brief Summary: Graves' disease is an autoimmune thyroid disorder characterized by the production of autoantibodies against the thyroid-stimulating hormone receptor (TRAb), leading to excessive thyroid hormone secretion and systemic manifestations. A subset of patients develop refractory disease, failing to achieve durable remission despite prolonged antithyroid therapy.
This study aims to evaluate the safety and efficacy of HN2301, an in vivo CAR-T therapy in which host T lymphocytes are engineered and transformed to functional CAR-T cells via CD8 antibody-coated LNP d...